ADVM - アバランシェ・バイオテクノロジ―ズ (Adverum Biotechnologies Inc.) アバランシェ・バイオテクノロジ―ズ

 ADVMのチャート


 ADVMの企業情報

symbol ADVM
会社名 Adverum Biotechnologies Inc (アバランシェ・バイオテクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Adverum Biotechnologies Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. It has collaboration agreements with Regeneron Pharmaceuticals to research develop and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Its core capabilities include clinical development and in-house manufacturing specifically in process development and assay development.   アバランシェ・バイオテクノロジ―ズは、米国のバイオ医薬品会社。眼科疾患用の新規遺伝子治療薬の発見、開発および商業化に従事。主な製品は、滲出型加齢黄斑変性症の遺伝子治療薬「AVA-101」やX染色体連鎖性網膜分離症(XLRS)の遺伝子治療薬「AVA-311」。本社は、カリフォルニア州メンロ・パ―ク。   Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.
本社所在地 1035 O'Brien Drive Menlo Park CA 94025 USA
代表者氏名 Paul B. Cleveland ポールB.クリーブランド
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 650-272-6269
設立年月日 38899
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 78人
url www.avalanchebiotech.com
nasdaq_url https://www.nasdaq.com/symbol/advm
adr_tso
EBITDA EBITDA(百万ドル) -65.87600
終値(lastsale) 5.51
時価総額(marketcap) 345444347.74
時価総額 時価総額(百万ドル) 359.86400
売上高 売上高(百万ドル) 1.63300
企業価値(EV) 企業価値(EV)(百万ドル) 124.98800
当期純利益 当期純利益(百万ドル) -54.46500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Adverum Biotechnologies Inc revenues decreased 23% to $709K. Net loss increased 31% to $36M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development -gross increase of 39% to $20.8M (expense) Stock-based Compensation in SGA increase from $1.5M to $6.1M (expense).

 ADVMのテクニカル分析


 ADVMのニュース

   Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock  2020/08/13 01:37:44 GlobeNewswire
REDWOOD CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting…
   Adverum Biotechnologies : Virtual IR/KOL Event August 10, 2020 | MarketScreener  2020/08/10 22:04:05 MarketScreener
Virtual IR/KOL Event August 10, 2020 Forward-looking Statements Statements contained in… | August 11, 2020
   Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter 2020 Financial Results  2020/08/10 20:00:00 GlobeNewswire
-- Continued robust treatment response from both high and low doses -- -- Long-term durability beyond 15 months from single IVT injection with zero…
   Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Provide Corporate Update  2020/07/29 20:05:00 GlobeNewswire
REDWOOD CITY, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting…
   The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact  2020/06/24 12:07:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Provide Corporate Update  2020/07/29 20:05:00 GlobeNewswire
REDWOOD CITY, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting…
   The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact  2020/06/24 12:07:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout  2020/06/23 11:57:59 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Affimed NV (NASDAQ: AFMD ) - announced presentation at the AACR Virtual Meeting II, data on the Bristol-Myers Squibb Co (NYSE: BMY ) unit Genentech's RO7297089 and AFM24 developed from Affimed's ROCK platform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) (presented at the AACR Virtual Meeting II with pre-clinical data for oncology product candidate) Atossa Therapeutics Inc (NASDAQ: ATOS ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (announced full exercise of over-allotment option in IPO) Cytokinetics, Inc. (NASDAQ: CYTK ) Dyadic International, Inc. (NASDAQ: DYAI ) Evoke Pharma Inc (NASDAQ: EVOK ) ( announced FDA approval for inhaled formulation of its gastroparesis drug) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (moved higher on an analyst upgrade) GENMAB A/S/S ADR (NASDAQ: GMAB ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Halozyme Therapeutics, Inc.
   The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs  2020/06/19 11:41:54 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 18) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Alpine Immune Sciences Inc (NASDAQ: ALPN )( announced a licensing agreement with AbbVie Inc (NYSE: ABBV ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Castle Biosciences Inc (NASDAQ: CSTL ) Cytokinetics, Inc. (NASDAQ: CYTK ) DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) Neubase Therapeutics Inc (NASDAQ: NBSE ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Ovid Therapeutics Inc (NASDAQ: OVID ) Passage Bio Inc (NASDAQ: PASG ) Pliant Therapeutics Inc (NASDAQ: PLRX ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Royalty Pharma plc (NASDAQ: RPRX ) (IPOed Monday) Sarepta Therapeutics Inc (NASDAQ: SRPT )(announced a licensing agreement with Selecta Biosciences Inc (NASDAQ: SELB ) for licensing the latter's immune tolerance platform, ImmTOR for use in Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TELA Bio Inc (NASDAQ: TELA ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Trevena Inc (NASDAQ: TRVN ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 18) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Stocks In Focus Mylan Wins Patent Lawsuit Against Biogen With Respect To Multiple Sclerosis Drug Mylan NV (NASDAQ: MYL ) said the U.S.
   Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?  2020/05/25 15:30:09 Zacks Investment Research
Is (ADVM) Outperforming Other Medical Stocks This Year?
   Is Adverum Biotechnologies (ADVM) Outperforming Other Medical Stocks This Year?  2020/05/07 15:30:16 Zacks Investment Research
Is (ADVM) Outperforming Other Medical Stocks This Year?
   The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom to Join S&P 500  2020/05/07 11:41:00 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) (reacted to its first-quarter results and clinical pipeline update) AstraZeneca plc (NYSE: AZN ) ( announced FDA approval for label expansion for its Farxiga) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) Catalent Inc (NYSE: CTLT ) Cytosorbents Corp (NASDAQ: CTSO ) (reacted to its strong first-quarter results) DexCom, Inc. (NASDAQ: DXCM ) GENMAB A/S/S ADR (NASDAQ: GMAB ) (announced first-quarter results) Horizon Therapeutics PLC (NASDAQ: HZNP ) (reacted to first-quarter results) I mara Inc (NASDAQ: IMRA ) Immunomedics, Inc. (NASDAQ: IMMU ) Immunovant Inc (NASDAQ: IMVT ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) MacroGenics Inc (NASDAQ: MGNX ) (reacted to its first-quarter results and sell-side reactions to the results) Masimo Corporation (NASDAQ: MASI ) Meridian Bioscience, Inc.
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   Here's Why Momentum Investors Will Love Adverum Biotechnologies (ADVM)  2020/04/28 16:00:11 Zacks Investment Research
Does Adverum Biotechnologies (ADVM) have what it takes to be a top stock pick for momentum investors? Let's find out.
   Why Earnings Season Could Be Great for Adverum (ADVM)  2020/03/11 13:46:00 Zacks Investment Research
Adverum (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アバランシェ・バイオテクノロジ―ズ ADVM Adverum Biotechnologies Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)